acquisitions
Mylan to relaunch $27.1bn hostile takeover of Perrigo
September 10, 2015Sales and Marketing Mylan Perrigo, acquisitions, hostile bid, mergers, takeover
Mylan is to make yet another hostile $27.1 billion bid for Irish over the counter drug manufacturer Perrigo on Monday, …
Shire goes public with rejected $30bn Baxalta bid
August 5, 2015Research and Development, Sales and Marketing Baxalta, Shire, acquisitions, baxter, mergers, rare disease
Shire has confirmed that it made an all-share $30 billion offer to buy Baxalta last month, citing ’a strong strategic …
CSL completes $275m Novartis vaccines acquisition
August 3, 2015Manufacturing and Production, Sales and Marketing CSL, Novartis, acquisitions, asset swap, vaccines
CSL Limited has finalised its transaction to acquire Novartis’s global influenza vaccine business for $275 million. The move means Novartis …
Valeant in $800 million deal for Amoun Pharma
July 20, 2015Sales and Marketing Amoun, Egypt, MENA, Valeant, acquisitions
Valeant is striking out in the acquisitions market yet again, having agreed an $800 million deal to buy Egypt’s largest …
Celgene to acquire Receptos in $7.2bn deal
July 15, 2015Sales and Marketing Celgene, Crohn's, Crohn’s disease, Receptos, acquisitions, crohn's disease, mergers, multiple sclerosis, ozanimod, relapsing multiple sclerosis, ulcerative colitis
Celgene has boosted its immune and inflammatory disease pipeline with the purchase of the biopharma company Receptos for $7.2 billion. …
Pharma dominates global M&A activity
July 10, 2015Sales and Marketing M&A, MA, acquisitions, mergers, takeovers
Mergers and acquisitions in the pharma, medical and biotech sectors have hit the highest levels in nearly 15 years, a …
Horizon attempts a hostile $3bn Depomed takeover
July 9, 2015Manufacturing and Production, Research and Development, Sales and Marketing Depomed, M&A, MA, acquisitions, horizon, mergers, takeover
Dublin-based specialty pharmaceutical company Horizon has launched a bid to buy Depomed for $3 billion. Horizon, a biopharma company focussed …
Bristol-Myers Squibb: following the string of pearls
September 8, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, BMS, GSK, Johanna Mercier, Pfizer, UCB, Yervoy, acquisitions
Bristol-Myers Squibb (BMS) is something of an enigma in the pharma industry. Whilst many of its big pharma peers are …
Latest content
Dermatology leader Doncker is new Onicor CEO
